Idarubicin

1 Drug classified under this active ingredient

Idarubicin (HCl) 10 mg.
Vial. Powd. for concentr. for inf.  
For IV use only. Not for intrathecal use.
Dosage is calc. on the basis of body surface area.
Acute non- lymphocytic leukaemia (ANLL)
Adults - 12 mg/m²/d i.v. daily for 3 days in combin. with cytarabine.
or - 8 mg/m²/d i.v. daily for 5 days with/without combin.
Acute lymphocytic leukaemia (ALL)
Adults As sgle agent 12 mg/m² i.v. daily for 3 days.
Children  10 mg/m² i.v. daily for 3 days, as a sgle agent.
Admin. of a sec. course to be delayed in pts who develop sev. mucositis until recovery and dose reduct. of 25% is recomm. See lit.
Antimitotic and cytotox. agent. Ac. non-lymphocytic leukemia (ANLL) in adlts for remission induct. in untr. pts or for remission induct. in relapsed or refractory pts. Ac. lymphocytic leukemia (ALL) as second- line tmt in adlts and childr.
C/I: known hypersens. to act. subst. or to excip. and/or to other anthracyclines or anthracenediones • patients with heart dis. and myocardial failure • severe renal impairment • severe hepatic impairment • uncontrolled infections • breast-feeding • attenuated live vacc. and for the 6 months following the discont. of chemother. • severe HF • MI in the previous six months • severe cardiomyopathy • severe arrhythmia • persist. myelosuppression, • prev. tmt with idarubicin and/or other anthracyclines or anthracenediones at the max. cumulate. dose